Journal of Critical Care
Volume 24, Issue 1 , Pages 50-57 , March 2009

Fumarates: Unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine

References 

  1. Savarese JJ, Kitz RJ. Does clinical anesthesia need new neuromuscular blocking agents?. Anesthesiology. 1975;42:236–239
  2. Berg H, Roed J, Viby Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 41:1095-1103;41.
  3. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107:130–137
  4. Boros EE, Bigham EC, Mook RA, et al. Bis- and mixed-tetrahydroisoquinolinium chlorofumarates: new ultra-short-acting nondepolarizing neuromuscular blockers. J Med Chem. 1999;42:206–209
  5. Samano V, Ray JA, Thompson JB, et al. Synthesis of ultra-short-acting neuromuscular blocker GW 0430: A remarkably stereo- and regioselective synthesis of mixed tetrahydroisoquinolinium chlorofumarates. Org Lett. 1999;1:1993–1996
  6. Boros EE, Samano V, Ray JA, et al. Neuromuscular blocking activity and therapeutic potential effect of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys. J Med Chem. 2003;46:2502–2515
  7. Haijan Z, Sacchetti M. Solid state characterization of an neuromuscular blocking agent—GW280430A. Int J Pharm. 2002;234:19–23
  8. Boros EE, Samano V, Ray JA, Thompson JB, Jung DK, Kaldor I, et al. Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys. J Med Chem. 2003;46:2502–2515
  9. Savarese JJ, Belmont MR, Hashim MA, et al. Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat. Anesthesiology. 2004;100:835–845
  10. Belmont MR, Lien CA, Tjan J, Bradley E, Stein B, Patel SS, et al. Clinical pharmacology of GW280430A in humans. Anesthesiology. 2004;100:768–773
  11. Belmont MR, Lien CA, Savarese JJ, Patel S, Fisher G, Mook R. Neuromuscular blocking effects of GW280430Aat the adductor pollicis and larynx in human volunteers. Br J Anaesth. 1999;82:A419
  12. Cronnelly R, Morris RB, Miller RD. Edrophonium: duration of action and atropine requirements in humans during halothane anesthesia. Anesthesiology. 1982;57:261–266
  13. Belmont MR, Horochiwsky Z, Eliazo RF, Savarese JJ. Reversal of AV430A with cysteine in rhesus monkeys. Anesthesiology. 2004;0:A1180
  14. Heerdt PM, Kang R, Andrew T, Hashim M, Mook RJ, Savarese JJ. Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs. Anesthesiology. 2004;100:846–851
  15. Glaxo Wellcome Report No. RD2000/0016/00: A novel formulation-based approach to inhibition of GW280A-induced histamine release. Submitted as part of an IND Annual Report. 09 April 2002 (Serial Np. 008).
  16. Belmont MR, Lien CA, Tjan J, Patel S. Preliminary cardiovascular safety profile of AV430A in human volunteers. Anesthesiology. 2004;101:A1145
  17. Savarese JJ, Belmont MR, Cohn DL, et al. Some SAR among isoquinolinium fumarate diesters leading to identification of AV 002. Anesthesiology. 2007;107:A386
  18. Belmont MR, Savard P, Vasquez A, et al. A promising cysteine-reversible intermediate duration neuromuscular blocker in rhesus monkeys. Anesthesiology. 2007;107:A986
  19. Savard PMC, Belmont MR, Cross WM, et al. Comparative reversal of AV002 with cysteine and glutathione versus neostigmine in rhesus monkeys. Anesthesiology. 2007;107:A987
  20. Beattie WS, Buckley DN, Forrest JB. Continuous infusions of atracurium and vecuronium, compared with intermittent boluses of pancuronium: dose requirements and reversal. Can J Anaesth. 1992;39:925–931
  21. Beemer GH, Goonetilleke PH, Bjorksten AR. The maximum depth of an atracurium neuromuscular block antagonized by edrophonium to effect adequate recovery. Anesthesiology. 1995;82:852–858
  22. Savarese JJ, Belmont MR, Kraus K, et al. The new intermediate-duration nondepolarizing relaxant AV 002 has high autonomic safety in the cat. Anesthesiology. 2007;107:A984
  23. Muir AW, Sleigh T, Marshall RJ, et al. Neuromuscular blocking and cardiovascular effects of ORG 9487, a new short-acting aminosteroidal blocking agent, in anesthetized animals and in isolated muscle preparations. Eur J Anesthesiol. 1998;15:467–479
  24. Heerdt PM, Malhotra JK, Pan BY, et al. Cardiopulmonary effects of the novel neuromuscular blocking drug AV 002 in the dog. Anesthesiology. 2007;107:A983
  25. Belmont MR, Savard P, Cross WM, et al. The hemodynamic profile of increasing doses of AV 002 in rhesus monkeys. Anestheisology. 2007;107:A387

PII: S0883-9441(08)00240-2

doi: 10.1016/j.jcrc.2008.11.001

Journal of Critical Care
Volume 24, Issue 1 , Pages 50-57 , March 2009

Article Tools

* Image Usage & Resolution